Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 17/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
| ▸ | CASP7 | P55210 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7694200 | 0.84 | ALDH1A1 (0.63) | ALDH1A1TSHRCYP1A2CYP3A4HSD17B10 | |
| SCHEMBL15084646 | 0.82 | ALDH1A1 (0.57) | ALDH1A1TSHRCYP1A2CYP3A4HSD17B10 | |
| SCHEMBL31555718 | 0.81 | ALDH1A1 (0.54) | ALDH1A1TSHRCYP1A2CYP3A4HSD17B10 | |
| SCHEMBL797342 | 0.78 | ALDH1A1 (0.62) | ALDH1A1TSHRCYP1A2CYP3A4HSD17B10 | |
| SCHEMBL5591875 | 0.78 | ALDH1A1 (0.55) | ALDH1A1TSHRCYP1A2CYP3A4HSD17B10 | |
| SCHEMBL2210585 | 0.78 | ALDH1A1 (0.71) | ALDH1A1TSHRCYP1A2CYP3A4HSD17B10 | |
| SCHEMBL21050840 | 0.77 | ALDH1A1 (0.54) | ALDH1A1TSHRCYP1A2CYP3A4HSD17B10 | |
| SCHEMBL2209335 | 0.75 | ALDH1A1 (0.76) | ALDH1A1TSHRCYP1A2CYP3A4HSD17B10 | |
| SCHEMBL3583405 | 0.75 | ALDH1A1 (1.00) | ALDH1A1TSHRCYP1A2CYP3A4HSD17B10 | |
| SCHEMBL25418982 | 0.75 | ALDH1A1 (0.59) | ALDH1A1TSHRCYP1A2CYP3A4HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10710996-B2 | Pyrido-azaheterecydic compound and preparation method and use thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2020-07-14 | — | — | US | disclosed |
| WO-2016184434-A1 | PYRIDO-AZAHETERECYDIC COMPOUND AND PREPARATION METHOD AND USE THEREOF | 中国科学院上海药物研究所 | 2016-11-24 | — | — | WO | disclosed |
| WO-2007113565-A1 | NAPHTHYRIDINE DERIVATIVES AS ANTI-CANCER AGENTS | ASTRAZENECA AB (SE) | 2007-10-11 | — | — | WO | disclosed |
| EP-1724268-A1 | COMPOUND HAVING TGF-BETA INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | KIRIN BEER KABUSHIKI KAISHA (JP) | 2006-11-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10710996-B2 | Pyrido-azaheterecydic compound and preparation method and use thereof | MET, MERTK, DMPK | ALDH1A1 2733/4885TSHR 3370/4885CYP1A2 1997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.